<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202657</url>
  </required_header>
  <id_info>
    <org_study_id>2005-03</org_study_id>
    <nct_id>NCT00202657</nct_id>
  </id_info>
  <brief_title>Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide</brief_title>
  <official_title>Etude Observationnelle Des Valvulopathies Chez Les Patients Parkinsoniens Traites Par Pergolide Par Rapport a Une Population Temoin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Société Française de Cardiologie</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with Parkinson's disease and&#xD;
      treated with pergolide have a higher risk of heart valve disease compared to patients with&#xD;
      Parkinson's disease not treated with pergolide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pergolide is an ergot dopamine receptor agonist with demonstrated efficacy in Parkinson's&#xD;
      disease. Last year, two studies showed that pergolide can induce unexpected heart valve&#xD;
      disease potentially severe and frequent. The late discovery of this unknown side effect had&#xD;
      dramatic consequences in Parkinson's disease management and the French drug agency (AFFSAPS)&#xD;
      has recently published guidelines for its prescription. Little is known about the prevalence&#xD;
      and the molecular mechanisms leading to this adverse event. To determine the prevalence,&#xD;
      evolution, and potential risk factors of pergolide-induced heart valve disease, we propose an&#xD;
      echocardiographic observational study in parkinsonian patients taking pergolide compared to&#xD;
      matched controls. This clinical study will be performed in the Clinical Investigation Centre&#xD;
      in collaboration with the Institute of Cardiology of the Salpétrière Hospital&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>February 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">149</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Pergolide</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>echocardiography</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Pergolide for Parkinson disease or Patients with parkinson disease&#xD;
        not treated with Pergolide&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic Parkinson's disease&#xD;
&#xD;
          -  Hoehn and Yahr score inferior or equal to 4&#xD;
&#xD;
          -  treated with pergolide since more than 3 months (pergolide group)&#xD;
&#xD;
          -  never treated by pergolide (control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parkinson + syndrome, multiple system atrophy, supranuclear palsy&#xD;
&#xD;
          -  hoehn and yahr score equal to 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe CORVOL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigation Centre, Pitie-Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <keyword>parkinson's disease</keyword>
  <keyword>pergolide</keyword>
  <keyword>heart valve disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

